Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Identification of prostate cancer antigens by automated high-throughput filter immunoscreening.

Alsøe L, Stacy JE, Fosså A, Funderud S, Brekke OH, Gaudernack G.

J Immunol Methods. 2008 Jan 31;330(1-2):12-23. Epub 2007 Nov 20.

PMID:
18045611
2.

Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines.

Nygren MK, Døsen G, Hystad ME, Stubberud H, Funderud S, Rian E.

Br J Haematol. 2007 Feb;136(3):400-13. Epub 2006 Dec 8.

PMID:
17156404
3.

Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis.

Døsen G, Tenstad E, Nygren MK, Stubberud H, Funderud S, Rian E.

BMC Immunol. 2006 Jun 29;7:13.

4.

CD10+ stromal cells form B-lymphocyte maturation niches in the human bone marrow.

Torlakovic E, Tenstad E, Funderud S, Rian E.

J Pathol. 2005 Feb;205(3):311-7.

PMID:
15682430
5.

[Clinical use of haematopoietic stem cells from cord blood].

Lyngstadaas A, Husebekk A, Funderud S, Brinch L.

Tidsskr Nor Laegeforen. 2004 Nov 18;124(22):2928-31. Review. Norwegian.

6.

Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display.

Fosså A, Alsøe L, Crameri R, Funderud S, Gaudernack G, Smeland EB.

Cancer Immunol Immunother. 2004 May;53(5):431-8. Epub 2004 Jan 28.

PMID:
14747957
7.

Characterization of the novel human transmembrane protein 9 (TMEM9) that localizes to lysosomes and late endosomes.

Kveine M, Tenstad E, Døsen G, Funderud S, Rian E.

Biochem Biophys Res Commun. 2002 Oct 4;297(4):912-7.

PMID:
12359240
8.

Characterization, expression and functional aspects of a novel protein tyrosine phosphatase epsilon isoform.

Wabakken T, Hauge H, Funderud S, Aasheim HC.

Scand J Immunol. 2002 Sep;56(3):276-85.

9.

[Stem cells in adults].

Borge OJ, Funderud S.

Tidsskr Nor Laegeforen. 2001 Aug 30;121(20):2398-401. Review. Norwegian.

PMID:
11603050
10.

A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes.

Aasheim HC, Munthe E, Funderud S, Smeland EB, Beiske K, Logtenberg T.

Blood. 2000 Jan 1;95(1):221-30.

PMID:
10607706
11.

The nature of the subset of MHC class II molecules carrying the CDw78 epitopes.

Drbal K, Angelisová P, Rasmussen AM, Hilgert I, Funderud S, Horejsí V.

Int Immunol. 1999 Apr;11(4):491-8.

PMID:
10323201
12.

CDw78--a determinant on a major histocompatibility complex class II subpopulation that can be induced to associate with the cytoskeleton.

Rasmussen AM, Horejsí V, Levy FO, Blomhoff HK, Smeland EB, Beiske K, Michaelsen TE, Gaudernack G, Funderud S.

Eur J Immunol. 1997 Dec;27(12):3206-13.

PMID:
9464807
13.

Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood.

Naume B, Borgen E, Beiske K, Herstad TK, Ravnås G, Renolen A, Trachsel S, Thrane-Steen K, Funderud S, Kvalheim G.

J Hematother. 1997 Apr;6(2):103-14.

PMID:
9131439
14.

Purging of tumor cells from leukapheresis products: experimental and clinical aspects.

Kvalheim G, Wang MY, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaløy S, Smeland E, Funderud S, Fodstad O.

J Hematother. 1996 Aug;5(4):427-36. Review.

PMID:
8877718
15.

Solid-phase method for differential display of genes expressed in hematopoietic stem cells.

Røsok O, Odeberg J, Rode M, Stokke T, Funderud S, Smeland E, Lundeberg J.

Biotechniques. 1996 Jul;21(1):114-21.

16.

Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RI alpha 2 C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation.

Levy FO, Rasmussen AM, Taskén K, Skålhegg BS, Huitfeldt HS, Funderud S, Smeland EB, Hansson V.

Eur J Immunol. 1996 Jun;26(6):1290-6.

PMID:
8647207
17.

All-trans- and 9-cis-retinoic acid inhibit growth of normal human and murine B cell precursors.

Fahlman C, Jacobsen SE, Smeland EB, Lømo J, Naess CE, Funderud S, Blomhoff HK.

J Immunol. 1995 Jul 1;155(1):58-65.

PMID:
7602122
18.

Characterization of a promoter region supporting transcription of a novel human beta-galactoside alpha-2,6-sialyltransferase transcript in HepG2 cells.

Aas-Eng DA, Asheim HC, Deggerdal A, Smeland E, Funderud S.

Biochim Biophys Acta. 1995 Mar 14;1261(1):166-9.

PMID:
7893756
19.

All-trans retinoic acid directly inhibits granulocyte colony-stimulating factor-induced proliferation of CD34+ human hematopoietic progenitor cells.

Smeland EB, Rusten L, Jacobsen SE, Skrede B, Blomhoff R, Wang MY, Funderud S, Kvalheim G, Blomhoff HK.

Blood. 1994 Nov 1;84(9):2940-5.

PMID:
7524761
20.

Functional differences between CD38- and DR- subfractions of CD34+ bone marrow cells.

Rusten LS, Jacobsen SE, Kaalhus O, Veiby OP, Funderud S, Smeland EB.

Blood. 1994 Sep 1;84(5):1473-81.

PMID:
7520773
21.

Complement-mediated permeabilization of platelets by monoclonal antibodies to CD9: inhibition by leupeptin, and effects on the GP Ib-actin-binding protein system.

Solum NO, Rubach-Dahlberg E, Pedersen TM, Reisberg T, Høgåsen K, Funderud S.

Thromb Res. 1994 Aug 15;75(4):437-52.

PMID:
7997982
22.

A direct and effective immunomagnetic method for bone marrow purging in non-T ALL malignancies. The use of an anti-HLA-DR antibody gives sustained engraftment.

Wang MY, Fodstad O, Funderud S, Bengtsson M, Totterman T, Ludwig WD, Martin H, Kvalheim G.

Prog Clin Biol Res. 1994;389:119-24. No abstract available.

PMID:
7700893
23.

CDw75 antigen expression in human gastric carcinoma and adjacent mucosa.

David L, Nesland JM, Funderud S, Sobrinho-Simões M.

Cancer. 1993 Sep 1;72(5):1522-7.

PMID:
8348485
24.

CDw75 antigen expression in breast lesions.

Reed W, Erikstein BK, Funderud S, Lilleng R, Tvedt K, Nesland JM.

Pathol Res Pract. 1993 May;189(4):394-8.

PMID:
7688897
25.

Cell-specific expression of human beta-galactoside alpha 2,6-sialyltransferase transcripts differing in the 5' untranslated region.

Aasheim HC, Aas-Eng DA, Deggerdal A, Blomhoff HK, Funderud S, Smeland EB.

Eur J Biochem. 1993 Apr 1;213(1):467-75.

26.

Human Golgi beta-galactoside alpha-2,6-sialyltransferase generates a group of sialylated B lymphocyte differentiation antigens.

Keppler OT, Moldenhauer G, Oppenländer M, Schwartz-Albiez R, Berger EG, Funderud S, Pawlita M.

Eur J Immunol. 1992 Nov;22(11):2777-81.

PMID:
1425905
27.

[Sugar molecules, cell adhesion and cancer etiology].

Smeland EB, Funderud S.

Tidsskr Nor Laegeforen. 1992 Sep 20;112(22):2834. Norwegian. No abstract available.

PMID:
1412318
28.

Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells.

Smeland EB, Funderud S, Kvalheim G, Gaudernack G, Rasmussen AM, Rusten L, Wang MY, Tindle RW, Blomhoff HK, Egeland T.

Leukemia. 1992 Aug;6(8):845-52.

PMID:
1379314
29.

Cell cycle-dependent regulation of CDw75 (beta-galactoside alpha-2,6-sialyltransferase) on human B lymphocytes.

Erikstein BK, Funderud S, Beiske K, Aas-Eng A, De Lange Davies C, Blomhoff HK, Smeland EB.

Eur J Immunol. 1992 May;22(5):1149-55.

PMID:
1577059
30.

A new method for detachment of Dynabeads from positively selected B lymphocytes.

Rasmussen AM, Smeland EB, Erikstein BK, Caignault L, Funderud S.

J Immunol Methods. 1992 Feb 5;146(2):195-202.

PMID:
1371532
31.

Interleukin-7 differentiates a subgroup of acute lymphoblastic leukemias.

Skjønsberg C, Erikstein BK, Smeland EB, Lie SO, Funderud S, Beiske K, Blomhoff HK.

Blood. 1991 Jun 1;77(11):2445-50.

PMID:
2039826
32.

Cell cycle-specific expression and nuclear binding of DNA polymerase alpha.

Stokke T, Erikstein B, Holte H, Funderud S, Steen HB.

Mol Cell Biol. 1991 Jun;11(6):3384-9.

33.
34.

Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes.

Erikstein BK, Smeland EB, Blomhoff HK, Funderud S, Prydz K, Lesslauer W, Espevik T.

Eur J Immunol. 1991 Apr;21(4):1033-7.

PMID:
1850359
35.

Autologous transplantation of an immunomagnetic bead purged marrow in patients with relapsed acute lymphoblastic leukemia.

Körbling M, Knauf W, Funderud S, Kvalheim G, Hunstein W.

Haematologica. 1991 Mar;76 Suppl 1:29-36.

PMID:
1650742
36.

Immunomagnetic isolation of NK and LAK cells.

Naume B, Nonstad U, Steinkjer B, Funderud S, Smeland E, Espevik T.

J Immunol Methods. 1991 Jan 24;136(1):1-9.

PMID:
1704900
37.

Use of size fractionation of in vitro-activated human B lymphocytes for studies of cell cycle-dependent growth regulation.

Erikstein BK, Schwarze P, Blomhoff HK, Funderud S, Stokke T, Smeland EB.

Scand J Immunol. 1991 Jan;33(1):51-60.

PMID:
1899949
38.

Simultaneous assessment of chromatin structure, DNA content, and antigen expression by dual wavelength excitation flow cytometry.

Stokke T, Holte H, Erikstein B, Davies CL, Funderud S, Steen HB.

Cytometry. 1991;12(2):172-8.

39.

The B cell antigen CD75 is a cell surface sialytransferase.

Stamenkovic I, Asheim HC, Deggerdal A, Blomhoff HK, Smeland EB, Funderud S.

J Exp Med. 1990 Aug 1;172(2):641-3.

40.

Immunological typing of acute leukaemias by rosetting with immunomagnetic beads: comparison with immunofluorescence staining.

Skjønsberg C, Kiil Blomhoff H, Gaudernack G, Funderud S, Beiske K, Smeland EB.

Scand J Immunol. 1990 May;31(5):567-73.

PMID:
2189214
41.
42.

Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation.

Funderud S, Erikstein B, Asheim HC, Nustad K, Stokke T, Blomhoff HK, Holte H, Smeland EB.

Eur J Immunol. 1990 Jan;20(1):201-6.

PMID:
1689662
43.

Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes.

Smeland EB, Blomhoff HK, Funderud S, Shalaby MR, Espevik T.

J Exp Med. 1989 Oct 1;170(4):1463-8.

44.

Immunomagnetic removal of B-lymphoma cells using a novel mono-sized magnetizable polymer bead, M-280, in conjunction with primary IgM and IgG antibodies.

Kvalheim G, Fjeld JG, Pihl A, Funderud S, Ugelstad J, Fodstad O, Nustad K.

Bone Marrow Transplant. 1989 Sep;4(5):567-74.

PMID:
2790334
45.

Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens.

Holte H, Blomhoff HK, Beiske K, Funderud S, Torjesen P, Gaudernack G, Stokke T, Smeland EB.

Eur J Immunol. 1989 Jul;19(7):1221-5.

PMID:
2547623
46.

Heterogeneity of degradation of B-cell endocytosed monoclonal antibodies reacting with different sIgM epitopes.

Ruud E, Michaelsen T, Kindberg GM, Berg T, Funderud S, Godal T.

Scand J Immunol. 1989 Mar;29(3):299-308.

PMID:
2470135
47.

cAMP-mediated growth inhibition of a B-lymphoid precursor cell line Reh is associated with an early transient delay in G2/M, followed by an accumulation of cells in G1.

Blomhoff HK, Blomhoff R, Stokke T, deLange Davies C, Brevik K, Smeland EB, Funderud S, Godal T.

J Cell Physiol. 1988 Dec;137(3):583-7.

PMID:
2848044
48.

Transcription of protooncogenes during stimulation of normal human B lymphocytes.

Smeland EB, Blomhoff HK, Ohlsson R, De Lange Davies C, Funderud S, Boye E.

Eur J Immunol. 1988 Nov;18(11):1847-50.

PMID:
3060364
49.

Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation.

Kvalheim G, Funderud S, Kvaløy S, Gaudernack G, Beiske K, Jakobsen E, Jacobsen AB, Pihl A, Fodstad O.

J Natl Cancer Inst. 1988 Oct 19;80(16):1322-5.

PMID:
3050139
50.

Cyclic AMP has the ability to influence multiple events during B cell stimulation.

Holte H, Torjesen P, Blomhoff HK, Ruud E, Funderud S, Smeland EB.

Eur J Immunol. 1988 Sep;18(9):1359-66.

PMID:
2458941

Supplemental Content

Loading ...
Support Center